AI Summary
The content discusses the challenges in treating rectal cancer, focusing on the risk of distant metastasis despite primary tumor response. The article highlights two phase III trials that suggest intensified treatment regimens may benefit patients with locally advanced rectal cancer. It emphasizes the need for personalized treatment strategies, including organ preservation and biomarkers, to improve outcomes. The focus is on optimizing rectal cancer treatment towards personalization.
Rectal cancer remains a significant clinical challenge due to a persistent risk of distant metastasis despite improving response in the primary tumor. In this issue of the Annals of Oncology, two phase III randomized trials provide critical insights into the potential benefit of intensified treatment regimens for patients with locally advanced rectal cancer.1,2 This editorial highlights their exciting results and suggests areas for further improvement in treatment strategies, particularly concerning organ preservation and integral biomarkers needed to individualize therapies.